Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
rapilysin
actavis group ptc ehf - reteplasa - hjartadrep - blóðþurrðandi lyf - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
neotigason hart hylki 25 mg
teva b.v.* - acitretinum inn - hart hylki - 25 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
neotigason hart hylki 10 mg
teva b.v.* - acitretinum inn - hart hylki - 10 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
adrenalin mylan stungulyf, lausn 1 mg/ml
viatris limited - adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 1 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
marcain spinal stungulyf, lausn 5 mg/ml
aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 5 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
marcain spinal tung stungulyf, lausn 5 mg/ml
aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 5 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
protaminsulphat leo pharma stungulyf, lausn 10 mg/ml
leo pharma a/s* - protamini sulfas inn - stungulyf, lausn - 10 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
trandate stungulyf, lausn 5 mg/ml
aspen pharma trading limited - labetalolum hýdróklóríð - stungulyf, lausn - 5 mg/ml